Patents by Inventor Tibor Keler

Tibor Keler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies that bind human CD27 and uses thereof
    Patent number: 9169325
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: October 27, 2015
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • Monoclonal antibodies to dendritic cells
    Patent number: 9095626
    Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: August 4, 2015
    Assignee: CELLDEX THERAPEUTICS, INC.
    Inventors: Yashwant M. Deo, Tibor Keler, John Treml, Michael Endres
  • Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
    Patent number: 8586720
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: November 19, 2013
    Assignee: Celldex Therapeutics Inc.
    Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
  • Human monoclonal antibodies against protective antigen
    Patent number: 8404820
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: March 26, 2013
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
    Patent number: 8362214
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: January 29, 2013
    Assignee: Celldex Therapeutics Inc.
    Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
  • ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205)
    Publication number: 20120309031
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed.
    Type: Application
    Filed: July 6, 2012
    Publication date: December 6, 2012
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Lizhen HE, Venky RAMAKRISHNA, Laura A. VITALE
  • Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)
    Patent number: 8318165
    Abstract: The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: November 27, 2012
    Assignee: Celldex Therapeutics Inc.
    Inventors: Tibor Keler, Laura A. Vitale, Lizhen He
  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20120213771
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 23, 2012
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
    Patent number: 8236318
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 7, 2012
    Assignee: Celldex Therapeutics Inc.
    Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
  • MOLECULAR CONJUGATES COMPRISING HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS
    Publication number: 20120148596
    Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: February 15, 2012
    Publication date: June 14, 2012
    Applicant: CELLDEX RESEARCH CORPORATION
    Inventors: Yashwant M. DEO, Tibor KELER, John TREML, Michael ENDRES
  • HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
    Publication number: 20120114662
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: October 7, 2008
    Publication date: May 10, 2012
    Applicant: MEDAREX, INC.
    Inventors: Tibor KELER, Israel LOWY, Laura A. VITALE, Diann BLANSET, Mohan SRINIVASAN
  • Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cells
    Patent number: 8142790
    Abstract: The present invention provides novel methods for targeting an antigen to a dendritic cell using an antibody linked to the antigen. The present invention further provides methods of inducing or enhancing an immune response and methods of immunization using an antibody linked to the antigen.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: March 27, 2012
    Assignee: Celldex Research Corporation
    Inventors: Yashwant M. Deo, Tibor Keler, John Treml, Michael Endres
  • METHODS OF USING MOLECULAR CONJUGATES COMPRISING MONOCLONAL ANTIBODIES TO DENDRITIC CELLS
    Publication number: 20120039869
    Abstract: The present invention provides novel methods for targeting an antigen to a dendritic cell using an antibody linked to the antigen. The present invention further provides methods of inducing or enhancing an immune response and methods of immunization using an antibody linked to the antigen.
    Type: Application
    Filed: November 26, 2008
    Publication date: February 16, 2012
    Applicant: CELLDEX RESEARCH CORPORATION
    Inventors: Yashwant M. DEO, Tibor KELER, John TREML, Michael ENDRES
  • Human monoclonal antibodies against CD30
    Patent number: 8088377
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: January 3, 2012
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20110274685
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 10, 2011
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Human monoclonal antibodies against CD30
    Publication number: 20100322920
    Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: April 4, 2008
    Publication date: December 23, 2010
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
  • ANTIBODIES AGAINST HUMAN MELANOMA-ASSOCIATED CHONDROITIN SULPHATE PROTEOGLYCAN (MCSP)
    Publication number: 20100303816
    Abstract: The present invention provides isolated antibodies (e.g., humanized or human antibodies) that bind to the membrane-proximal domain (MP) of human Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), and are capable of mediating cytolysis of a cell expressing MCSP in the presence of human effector cells or complement. Methods of using such antibodies to induce cytolysis (e.g., ADCC or CDCC) of cells expressing MP-MCSP are also provided.
    Type: Application
    Filed: September 10, 2007
    Publication date: December 2, 2010
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor Keler, Laura A. Vitale, Lizhen He
  • Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
    Publication number: 20100098704
    Abstract: Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 5, 2009
    Publication date: April 22, 2010
    Applicant: Celldex Therapeutics Inc.
    Inventors: Tibor Keler, Lizhen He, Venky Ramakrishna, Laura A. Vitale
  • ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
    Publication number: 20090324622
    Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.
    Type: Application
    Filed: July 2, 2009
    Publication date: December 31, 2009
    Inventors: Tibor KELER, Michael ENDRES, Lizhen HE, Venky RAMAKRISHNA
  • Human monoclonal antibodies to dendritic cells
    Patent number: 7563876
    Abstract: Isolated human monoclonal antibodies and antigen-binding portions thereof which specifically bind to dendritic cells are disclosed. Also disclosed are bispecifics, immunotoxins and antigen conjugates which include the antibodies or antibody portions. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: July 21, 2009
    Assignee: CellDex Therapeutics, Inc.
    Inventors: Yashwant M. Deo, Tibor Keler, John Treml